The GenOptics platform, centred on SPRi technology, enables:

- The generation of biochips bearing a large range of peptide probes (peptide arrays)

- The label-free detection of peptide-antibody interactions in complex media such as undiluted sera varied according to the patient and the peptide, revealing donor-related differences in the anti-HCV antibody responses (specificity, amount and affinity).

The GenOptics SPRi technology is a powerful tool for clinical applications such as diagnosis, pharmacologic studies, and for research.